ライフサイエンスコーパス: gastrointestinal bleeding

1 prolonged bleeding times, and cutaneous and gastrointestinal bleeding).

2 e the association between SSRI use and upper gastrointestinal bleeding.

3 ajor bleeding, intracranial haemorrhage, and gastrointestinal bleeding.

4 ajor bleeding as for warfarin, but increased gastrointestinal bleeding.

5 tonin transporter were associated with upper gastrointestinal bleeding.

6 the relationship between SSRI use and upper gastrointestinal bleeding.

7 tionally, TSOACs do not increase the risk of gastrointestinal bleeding.

8 days) is significantly associated with upper gastrointestinal bleeding.

9 D), a group with a high risk of both VTE and gastrointestinal bleeding.

10 ed to elderly patients increases the risk of gastrointestinal bleeding.

11 clinically significant risk for NOAC-related gastrointestinal bleeding.

12 venting clinically important and overt upper gastrointestinal bleeding.

13 reases the risks for portal hypertension and gastrointestinal bleeding.

14 proved outcomes in patients with acute upper gastrointestinal bleeding.

15 PPIs are commonly used to prevent gastrointestinal bleeding.

16 reasingly recognized as important sources of gastrointestinal bleeding.

17 Is in selected high-risk patients to prevent gastrointestinal bleeding.

18 ize cardiac benefit and minimize the risk of gastrointestinal bleeding.

19 ble tool for detecting the location of acute gastrointestinal bleeding.

20 ia, vascular malformations that cause severe gastrointestinal bleeding.

21 actic use of a PPI reduced the rate of upper gastrointestinal bleeding.

22 s but are associated with increased risks of gastrointestinal bleeding.

23 se, small-bowel obstruction, and unexplained gastrointestinal bleeding.

24 ers that cause abdominal pain, diarrhea, and gastrointestinal bleeding.

25 All patients had complete relief from gastrointestinal bleeding.

26 peutic strategies in the management of lower gastrointestinal bleeding.

27 an important role in the management of lower gastrointestinal bleeding.

28 ces in the diagnosis and management of upper gastrointestinal bleeding.

29 d the majority (43 of 52) did so for obscure gastrointestinal bleeding.

30 inal bleeding and 86% of patients with lower gastrointestinal bleeding.

31 ous proton pump inhibitors in reducing upper gastrointestinal bleeding.

32 No patients died directly of gastrointestinal bleeding.

33 hemorrhage with episodes of intracranial and gastrointestinal bleeding.

34 lopment of SIRS in patients hospitalized for gastrointestinal bleeding.

35 sfusion policies for adults with acute upper gastrointestinal bleeding.

36 appear with jaundice, weakness, wasting, and gastrointestinal bleeding.

37 were found to be at increased risk for major gastrointestinal bleeding.

38 considered fundamental for the diagnosis of gastrointestinal bleeding.

39 l RBC transfusion strategies for acute upper gastrointestinal bleeding.

40 age without hypertension or risk factors for gastrointestinal bleeding.

41 substantial risk of disabling or fatal upper gastrointestinal bleeding.

42 tically ill patients for prophylaxis against gastrointestinal bleeding.

43 cularly among the elderly-a greater risk for gastrointestinal bleeding.

44 (NSAIDs), which further increase the risk of gastrointestinal bleeding.

45 ain, signs of acute pancreatitis and massive gastrointestinal bleeding.

46 ransfusion for all patients with acute upper gastrointestinal bleeding.

47 atal bleeding, intracranial haemorrhage, and gastrointestinal bleeding.

48 risk of major bleeding (0.74; 0.60-0.91) and gastrointestinal bleeding (0.58; 0.41-0.82) versus dabig

49 (1 patient), vaginal bleeding (2 patients), gastrointestinal bleeding (1 patient), epistaxis (1 pati

50 r colorectal neoplasm (3 pts, 27%) and lower gastrointestinal bleeding (1 pts, 9%).

51 e (0.48, 0.39-0.59; p<0.0001), but increased gastrointestinal bleeding (1.25, 1.01-1.55; p=0.04).

52 od transfusion (10.4% versus 10.8%; P=0.70), gastrointestinal bleeding (1.4% versus 1.8%; P=0.35), or

53 acranial hemorrhage, 0.34 (0.26-0.46); major gastrointestinal bleeding, 1.28 (1.14-1.44); acute myoca

54 d 148 patients with severe nonvariceal upper gastrointestinal bleeding (125 with ulcers, 19 with Dieu

55 n (22 [2%] patients vs 33 [3%] patients) and gastrointestinal bleeding (13 [1%] vs ten [1%]).

56 The recurrence rates of gastrointestinal bleeding (18.3% vs. 33.9%, P = 0.004) a

57 alidated in 288 patients admitted with lower gastrointestinal bleeding (184 safely discharged) from t

58 leeding in 3 of 10 patients with symptoms of gastrointestinal bleeding (30%).

59 % vs. 40.8%, p = .004) and history of recent gastrointestinal bleeding (41% vs. 7%, p < .001) were mo

60 Gastrointestinal bleeding (61.7%) was the most frequent

61 ing pulmonary alveolar [11.8% and 15.6%] and gastrointestinal bleeding [7.8% and 9.4%]) was similar b

62 Upper gastrointestinal bleeding (76/211 vs. 36/ 200; p = .0196

63 r bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke

64 endoscopy was noted to be 68.1% for obscure gastrointestinal bleeding according to a systematic revi

65 circulating hormone and agent used to treat gastrointestinal bleeding, affects gastrointestinal moti

66 The authors explored the risk of upper gastrointestinal bleeding after short-term SSRI exposure

67 he adjusted odds ratio for the risk of upper gastrointestinal bleeding after SSRI exposure was 1.67 (

68 An elevated risk of upper gastrointestinal bleeding after SSRI exposure was seen i

69 lcer bleeding and in the management of upper gastrointestinal bleeding after successful hemostasis of

70 A PELD score of >/=15, history of gastrointestinal bleeding, age at FO initiation >/=16 wk

71 icle aims to evaluate the real world risk of gastrointestinal bleeding among users naive to dabigatra

72 mbolus, pneumothorax, myocardial infarction, gastrointestinal bleeding, anaphylaxis with a difficult

73 s accomplished in 77% of patients with upper gastrointestinal bleeding and 86% of patients with lower

74 group A, 137 patients (45.5%) presented with gastrointestinal bleeding and 98 (32.6%) presented with

75 INTRODUCTION: A decreased frequency of upper gastrointestinal bleeding and a possible association of

76 nagement of patients with unclear sources of gastrointestinal bleeding and allows for effective hemor

77 and hepatic encephalopathy are common after gastrointestinal bleeding and can be simulated by an ami

78 ing severe enough to result in massive upper gastrointestinal bleeding and death.

79 Drug-induced gastrointestinal bleeding and drug-induced pancreatitis

80 tral prosthesis dysfunction, with occasional gastrointestinal bleeding and gastrointestinal angiodysp

81 suspected pump thrombosis) and hemorrhagic (gastrointestinal bleeding and hemorrhagic stroke) events

82 (CVD) and low 10-year CVD risk, the risks of gastrointestinal bleeding and hemorrhagic strokes associ

83 Initially, he had abdominal pain, gastrointestinal bleeding and hypotension.

84 SIRS occurs in 27% of patients admitted for gastrointestinal bleeding and is associated with a poor

85 nsion prevented clinically significant upper gastrointestinal bleeding and maintained gastric pH of >

86 suspension is effective in preventing upper gastrointestinal bleeding and more effective than intrav

87 ary outcomes were clinically important upper gastrointestinal bleeding and overt upper gastrointestin

88 nrolled 921 patients with severe acute upper gastrointestinal bleeding and randomly assigned 461 of t

89 nes in management of acute nonvariceal upper gastrointestinal bleeding and reviews recent advances in

90 The current rate of upper gastrointestinal bleeding and the relative adverse effec

91 the very near future the detection of upper gastrointestinal bleeding and to survey high-risk patien

92 t to recognize potential etiologies of upper gastrointestinal bleeding and understand therapeutic mod

93 monary hypertension, and one episode each of gastrointestinal bleeding and wound healing complication

94 onship between the treatment effect (risk of gastrointestinal bleeding) and the classification used t

95 idal antiinflammatory medications in 6-month gastrointestinal bleeding, and a study of simvastatin +

96 n autologous transplant, had an infection or gastrointestinal bleeding, and also decreased with highe

97 tients with Crohn's disease, celiac disease, gastrointestinal bleeding, and anemia.

98 .25%) had hemorrhagic stroke, 107 (6.8%) had gastrointestinal bleeding, and five (0.3%) required majo

99 Intensive care unit admission, upper gastrointestinal bleeding, and high APACHE II scores are

100 of spontaneous bacterial peritonitis, upper gastrointestinal bleeding, and low-protein ascites with

101 e of SPECT/CT and CT angiography to evaluate gastrointestinal bleeding, and Meckel diverticulum imagi

102 oids presented significantly more often with gastrointestinal bleeding, and midgut carcinoids present

103 In patients with overt gastrointestinal bleeding, and negative findings on esop

104 stinal hypomotility, constipation, diarrhea, gastrointestinal bleeding, and pancreatitis in criticall

105 stinal hypomotility, constipation, diarrhea, gastrointestinal bleeding, and pancreatitis, and should

106 ites, patients that received antibiotics for gastrointestinal bleeding, and patients that required di

107 cirrhosis, patients with non-variceal upper gastrointestinal bleeding, and patients with ischaemic h

108 disease, gastroesophageal reflux disease, or gastrointestinal bleeding, and prior use of histamine-2

109 ntially requiring intubation; 18.4%), severe gastrointestinal bleeding/anemia (15.7%), stroke (9.7%),

110 Based on this study sample, occult gastrointestinal bleeding appears to be pervasive in the

111 Infections in cirrhotic patients with upper gastrointestinal bleeding are a common event causing sev

112 Transfusion thresholds for acute upper gastrointestinal bleeding are controversial.

113 The reasons for gastrointestinal bleedings are manifold.

114 of major gastrointestinal bleeding, with all gastrointestinal bleeding as a secondary outcome.

115 ial to the management of patients with upper gastrointestinal bleeding as meticulous hemostatic techn

116 lar to HHT patients, the mice also exhibited gastrointestinal bleeding, as evidenced by positive feca

117 of portal hypertension, hepatosplenomegaly, gastrointestinal bleeding, ascites, thrombocytopenia, es

118 This review will quantify the risk of gastrointestinal bleeding associated with common cardiop

119 nd that TIPS be avoided for the treatment of gastrointestinal bleeding associated with GVE.

120 (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient

121 There was no significant difference in major gastrointestinal bleeding between TSOACs and VKAs (RR 0.

122 te of readmission due to hemorrhagic stroke, gastrointestinal bleeding, bleeding causing anemia, and

123 Clinically significant upper gastrointestinal bleeding (bright red blood not clearing

124 e the risk of serious warfarin-related upper gastrointestinal bleeding, but the evidence of their eff

125 Localizing obscure gastrointestinal bleeding can be a clinical challenge, d

126 atistically lower mortality in patients with gastrointestinal bleeding compared with liberal transfus

127 ted with a reduced risk of all severities of gastrointestinal bleeding compared with warfarin (0.25 [

128 myocardial infarction or hospitalization for gastrointestinal bleeding compared with warfarin.

129 inal bleeding, which often presents as lower gastrointestinal bleeding, continues to be one of the mo

130 idered a complementary test in patients with gastrointestinal bleeding, Crohn's disease, or celiac di

131 Similarly, synthetic BS caused gastrointestinal bleeding, decreased ileal contact angle

132 Upper gastrointestinal bleeding developed in 6.1% of patients

133 he small bowel include evaluation of obscure gastrointestinal bleeding, diagnosis and surveillance of

134 One-third of patients admitted with upper gastrointestinal bleeding died within 60 days of admissi

135 cation systems for patients with acute upper-gastrointestinal bleeding discriminate between patients

136 This case presents a seldom cause of a gastrointestinal bleeding due to an aneurysma of the hep

137 .1% overall and 12.0% among those with lower gastrointestinal bleeding during pediatric colonoscopy.

138 nagement of patients presenting with obscure gastrointestinal bleeding during the period from 2005 to

139 2012 with use of dabigatran and at least one gastrointestinal bleeding episode.

140 ians should carefully monitor signs of upper gastrointestinal bleeding even after short-term exposure

141 he risk for major bleeding events, primarily gastrointestinal bleeding events, in both men and women.

142 0 to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bleeding events.

143 0 to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bleeding events.

144 rmed a significantly increased risk of lower gastrointestinal bleeding following polypectomy in patie

145 from the National Comparative Audit of Lower Gastrointestinal Bleeding from 143 hospitals in the UK i

146 Nine patients had gastrointestinal bleeding from an indeterminate source a

147 ancreatic necrosis, management of refractory gastrointestinal bleeding from gastric varix or vasculat

148 Upper gastrointestinal bleeding from peptic ulcer disease is n

149 Upper gastrointestinal bleeding from peptic ulcers or other no

150 Acute upper gastrointestinal bleedings from ulcers or esophago-gastr

151 To investigate the causes of gastrointestinal bleeding (GIB) and its impact on patien

152 are a fast emerging population vulnerable to gastrointestinal bleeding (GIB) due to their use of anti

153 The incidence of upper gastrointestinal bleeding (GIB) has not been reduced des

154 d the incidence, predictors, and outcomes of gastrointestinal bleeding (GIB) in patients with acute c

155 The risk factors and clinical sequelae of gastrointestinal bleeding (GIB) in the current era of dr

156 both the location and the severity of acute gastrointestinal bleeding (GIB) to optimize the diagnost

157 ther these drugs increase patients' risk for gastrointestinal bleeding (GIB).

158 sed, the incidence of clinically significant gastrointestinal bleeding, hospital-acquired pneumonia,

159 zations (HR, 1.07; 95% CI, 0.94-1.22) or non-gastrointestinal bleeding hospitalizations (HR, 0.98; 95

160 o significant reduction in the risk of other gastrointestinal bleeding hospitalizations (HR, 1.07; 95

161 , those without PPI co-therapy had 284 upper gastrointestinal bleeding hospitalizations per 10,000 pe

162 With respect to acute gastrointestinal bleeding, however, two well-conducted t

163 More gastrointestinal bleeding (HR, 1.14 [CI, 1.06 to 1.22];

164 terectomy included systemic infection in 11, gastrointestinal bleeding in 1, and severe electrolyte i

165 uiring reversal (n = 59; 70.2%), followed by gastrointestinal bleeding in 13 (15.5%) patients.

166 red seventy-seven consecutive admissions for gastrointestinal bleeding in 151 patients were evaluated

167 ompare rates of clinically significant upper gastrointestinal bleeding in a prospective, phase 3, dou

168 IEW: Colorectal polyps are a common cause of gastrointestinal bleeding in children.

169 of an old and possibly common cause of upper gastrointestinal bleeding in children.

170 ptor antagonists for the prevention of upper gastrointestinal bleeding in critically ill patients, pu

171 tingly, a significant lengthy control of the gastrointestinal bleeding in one of our patients was ach

172 of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding in patients with bleeding risk

173 tric and duodenal motility, risk factors for gastrointestinal bleeding in pediatric intensive care un

174 ions (age 75 years or older, peptic ulcer or gastrointestinal bleeding in the past year, or concurren

175 ration of fresh frozen plasma (FFP) prevents gastrointestinal bleeding in this individual, its effect

176 ted of 16 patients with clinical symptoms of gastrointestinal bleeding in whom features of active ble

177 Gastrointestinal bleeding incidence and case-fatality ra

178 cusses key issues in the management of upper gastrointestinal bleeding including patient preparation,

179 significant difference in the risk of upper gastrointestinal bleeding, infections, or mortality.

180 Major outcomes were clinically significant gastrointestinal bleeding, infective ventilator-associat

181 Previous major bleeding events were major gastrointestinal bleeding, intracranial bleeding, sponta

182 Common causes of anemia, such as gastrointestinal bleeding, iron/vitamin deficiencies, he

183 older with new presentations of acute upper gastrointestinal bleeding, irrespective of comorbidity,

184 Acute lower gastrointestinal bleeding is a common reason for emergen

185 Acute upper gastrointestinal bleeding is a leading indication for re

186 Upper gastrointestinal bleeding is a serious complication, but

187 Acute gastrointestinal bleeding is an emergency with a high mo

188 RECENT FINDINGS: Gastrointestinal bleeding is associated with higher rate

189 ss of transfusion strategies for acute upper gastrointestinal bleeding is both feasible and essential

190 nsfusion of red cells in patients with acute gastrointestinal bleeding is controversial.

191 Gastrointestinal bleeding is now associated with lower m

192 Acute upper gastrointestinal bleeding is one of the most common medi

193 UP in patients with low risk of stress ulcer gastrointestinal bleeding is prohibitive.

194 n the management of diverticulosis and lower gastrointestinal bleeding is uncertain.

195 luation and Management of Occult and Obscure Gastrointestinal Bleeding." It was approved by the Clini

196 often used to diagnose and treat acute upper gastrointestinal bleeding, its role in the management of

197 stem organ failure in 21 patients (75%); the gastrointestinal bleeding may have contributed to the on

198 rospective evaluation of patients with upper gastrointestinal bleeding, multivariate analysis demonst

199 symptoms at presentation are lower or upper gastrointestinal bleeding (n = 29, 33%), ascites (n = 23

200 amine-2 receptor blocker reduced the risk of gastrointestinal bleeding (odds ratio 0.47; 95% confiden

201 ulcer prophylaxis did not alter the risk of gastrointestinal bleeding (odds ratio 1.26; 95% confiden

202 isceral arteriography in patients with acute gastrointestinal bleeding of a protocol requiring a posi

203 d unchanged when all patient admissions with gastrointestinal bleeding of any source were included in

204 Occult gastrointestinal bleeding, often arising from the lower

205 e-phase acquisition in patients with obscure gastrointestinal bleeding (OGIB).

206 ease in aminotransferases (one), and grade 3 gastrointestinal bleeding (one).

207 Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes?

208 ears, but none of the 158 patients developed gastrointestinal bleeding or hypersplenism.

209 eivers were more likely to have had previous gastrointestinal bleeding or to present with cardiogenic

210 oses of acute myocardial infarction, stroke, gastrointestinal bleeding, or congestive heart failure o

211 , the critically ill, those with acute upper gastrointestinal bleeding, or for infants with low birth

212 sons (e.g., during chemotherapy, acute upper gastrointestinal bleeding, or in intensive care unit set

213 no increased incidence of renal dysfunction, gastrointestinal bleeding, or other adverse events.

214 tis, hepatic failure/cirrhosis with ascites, gastrointestinal bleeding, or postlaparotomy.

215 ardial infarction, congestive heart failure, gastrointestinal bleeding, or stroke or a diagnosis rela

216 infarction (AMI), congestive heart failure, gastrointestinal bleeding, or stroke or a diagnosis rela

217 P<0.001 and P=0.003, respectively) and upper gastrointestinal bleeding (P=0.03 and P=0.007, respectiv

218 CT) has also gained importance in diagnosing gastrointestinal bleeding, particularly in hemodynamical

219 Gastrointestinal bleeding, peptic ulcers, and polyps wer

220 o-therapy had 119 hospitalizations for upper gastrointestinal bleeding per 10,000 person-years of tre

221 of 359 case subjects hospitalized for upper gastrointestinal bleeding, perforation, or benign gastri

222 ing curve with regard to risks of stricture, gastrointestinal bleeding, perforation, or hospitalizati

223 .6% vs. 2.2%, p < 0.001) and higher rates of gastrointestinal bleeding, perforation, or infarction (1

224 ation (48%), followed by portal hypertensive gastrointestinal bleeding (PHGB) (32.5%), severe bacteri

225 y end points were hospitalizations for upper gastrointestinal bleeding potentially preventable by PPI

226 reinforce best-practice recommendations for gastrointestinal bleeding prevention among patients pres

227 nts and those with kidney disease had higher gastrointestinal bleeding rates with dabigatran.

228 hildren (mean age, 24 mo) who presented with gastrointestinal bleeding received endoscopic treatment

229 Age, sex, previous admission for lower gastrointestinal bleeding, rectal examination findings,

230 Gastrointestinal bleeding related to portal hypertension

231 .19-0.68; p = 0.002; I = 0%) and overt upper gastrointestinal bleeding (relative risk 0.35; 95% confi

232 nists at reducing clinically important upper gastrointestinal bleeding (relative risk 0.36; 95% confi

233 eceptor inhibitors (SSRIs) and risk of upper gastrointestinal bleeding remains controversial.

234 ild side effects occurred in seven (15%) and gastrointestinal bleeding requiring discontinuation of M

235 Gastrointestinal bleeding requiring transfusion was more

236 low-up of approximately 1000 days, recurrent gastrointestinal bleeding resulted from variceal hemorrh

237 T trial confirmed a substantial reduction in gastrointestinal bleeding risk without apparent increase

238 A substantial reduction in gastrointestinal bleeding risk without increase in cardi

239 Significantly higher gastrointestinal bleeding risks with dabigatran 150 mg (

240 ajor bleeding (RR, 0.80 [CI, 0.63 to 1.01]), gastrointestinal bleeding (RR, 1.30 [CI, 0.97 to 1.73]),

241 Gastrointestinal bleeding scintigraphy performed with (9

242 er gastrointestinal bleeding and overt upper gastrointestinal bleeding; secondary outcomes were nosoc

243 om pneumonia, shock or cardiac arrest, upper gastrointestinal bleeding, sepsis, or deep venous thromb

244 s withdrawn from the study because of severe gastrointestinal bleeding shortly before implantation, a

245 Guidelines for nonvariceal gastrointestinal bleeding should incorporate these resul

246 e in adults, in the investigation of obscure gastrointestinal bleeding, small bowel Crohn's disease,

247 Observed complications of treatment were gastrointestinal bleeding, small-bowel perforation, and

248 the novel oral anticoagulant (NOAC)-related gastrointestinal bleeding, summarize the management stra

249 odds ratio, 1.4 [CI, 0.9 to 2.0]) and major gastrointestinal bleeding (summary odds ratio, 1.7 [CI,

250 ficantly higher risk for hospitalization for gastrointestinal bleeding than dabigatran (p = 0.0416),

251 igatran was associated with a higher risk of gastrointestinal bleeding than VKA.

252 150 mg had a significantly greater hazard of gastrointestinal bleeding than warfarin (1.23; 1.01-1.50

253 rgoing endoscopy in intensive care units for gastrointestinal bleeding that developed while in the ho

254 eding) and the classification used to define gastrointestinal bleeding, the Jadad quality score nor t

255 as no alarming increase in the risk of upper gastrointestinal bleeding; the effect of proton pump inh

256 with reduced risk of warfarin-related upper gastrointestinal bleeding; the greatest reduction occurr

257 tect both the source and the cause of active gastrointestinal bleeding, thereby expediting treatment

258 zed had an episode of clinically significant gastrointestinal bleeding, three patients met the criter

259 ifferent prevention strategies against upper gastrointestinal bleeding (UGIB) in the general populati

260 Upper gastrointestinal bleeding (UGIB) is a common gastrointes

261 Upper gastrointestinal bleeding (UGIB) remains a common medica

262 We sought to quantify upper gastrointestinal bleeding (UGIB) risk associated with lo

263 ations were positively associated with upper gastrointestinal bleeding (UGIB) secondary to peptic ulc

264 Fifty-two patients on AT with upper gastrointestinal bleeding (UGIB) were evaluated.

265 low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB).

266 of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding using H2 blockers (1A) or prot

267 her the cost of treating patients with upper gastrointestinal bleeding varies among surgeons, interni

268 Apixaban lowers the risk of major and gastrointestinal bleeding versus dabigatran and rivaroxa

269 ssociated with anemia, which may result from gastrointestinal bleeding, vitamin deficiency, or liver-

270 The rate of overt upper gastrointestinal bleeding was also reduced with omeprazo

271 Initially the source of the gastrointestinal bleeding was caused by an ulcus Dieulaf

272 immediately in patients in whom substantial gastrointestinal bleeding was detected at scintigraphy.

273 Gastrointestinal bleeding was lower with dabigatran 110

274 Gastrointestinal bleeding was noted in 6 of 24 patients

275 alysis showed that the risk for hospitalized gastrointestinal bleeding was similar between the 2 drug

276 e-variant confounders, the incidence rate of gastrointestinal bleeding was similar during dabigatran

277 Gastrointestinal bleeding was the most frequent event.

278 A total of 5,377 patients with upper gastrointestinal bleeding were enrolled.

279 documented iron-deficiency anemia or active gastrointestinal bleeding were excluded from the study.

280 records of psychiatric inpatients with upper gastrointestinal bleeding were retrieved from the Taiwan

281 Obscure gastrointestinal bleeding, which often presents as lower

282 anagement challenge of having a high risk of gastrointestinal bleeding while taking anticoagulants.

283 performance to identify patients with lower gastrointestinal bleeding who are suitable for safe outp

284 e risk score to identify patients with lower gastrointestinal bleeding who could safely avoid hospita

285 1), whereas there was a greater incidence of gastrointestinal bleeding with abciximab (4.8% vs. 2.8%,

286 The risk of gastrointestinal bleeding with antiplatelet therapy is s

287 Excess risk for hemorrhagic stroke and gastrointestinal bleeding with aspirin, risk for CHD, th

288 anagement in about 50% of cases with obscure gastrointestinal bleeding with complete small bowel endo

289 The risk of major gastrointestinal bleeding with direct oral anticoagulant

290 We compared the risk of gastrointestinal bleeding with direct oral anticoagulant

291 r findings show no increase in risk of major gastrointestinal bleeding with direct oral anticoagulant

292 r findings show no increase in risk of major gastrointestinal bleeding with direct oral anticoagulant

293 hemic outcomes, despite a reduction in upper gastrointestinal bleeding with omeprazole.

294 mbers needed to treat (NNT) to prevent upper gastrointestinal bleeding with routine PPI co-prescripti

295 rovides an update on the management of upper gastrointestinal bleeding with special attention to pati

296 data are conflicting about the risk of major gastrointestinal bleeding with these drugs.

297 rospective studies that reported the risk of gastrointestinal bleeding with use of a direct oral anti

298 ascular outcomes but did show a reduction in gastrointestinal bleeding with use of a PPI.

299 ethrombosis of the portomesenteric veins and gastrointestinal bleeding, with a marginal 10-year overa

300 e primary outcome was the incidence of major gastrointestinal bleeding, with all gastrointestinal ble